Immunotherapy/chemotherapy study shows promise at ASCO 2020
A phase 2 immunotherapy clinical trial combining durvalumab, an immunotherapy drug, with standard treatment of Alimta (pemetrexed)/cisplatin has shown promising overall survival results.
The study enrolled 55 patients and showed a median survival of 20.1 months. Of those 55 patients, 31 demonstrated a partial response, and 22 had stable disease. Most frequently observed adverse events included fatigue, nausea, anemia, and constipation – all which are typically seen with platinum-based chemotherapy. Among adverse events that investigators thought were possibly related to immunotherapy are hypothyroidism and rashes.
On Friday, May 29, 2020, the full results of the “PrE0505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study” were reported on at the annual American Society of Clinical Oncology’s (ASCO) virtual meeting.
Learn more here: https://bit.ly/3eUhrgr